If monsoon is good, then company would be able to achieve 15%revenue growth guidance and deliver 18.5% earnings before interest, taxes, depreciation, and amortization (EBITDA) margin, said MK Dhanuka, Managing Director, Dhanuka Agritech.
Speaking to CNBC-TV18, he said the products launched in FY18 will see further traction in the current fiscal.
Out of the total turnover, two-third comes from specialty molecules and one-third from generic molecules, Dhanuka said.
Different products have different margins but in speciality molecules the gross margins are in the range of 40% and for generics in range of 10-20%, he added.
He said confirmed that there is no major capex planned in FY19, it will be only around Rs 10 crore.
Dhanuka Agritech posted decent set of number in the fourth quarter of FY18. The revenues were up 16% year-on-year (YoY) for the quarter and gross margins came in lower at 45% against 50% YoY due to product mix.